Regular Article CLINICAL TRIALS AND OBSERVATIONS Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
نویسندگان
چکیده
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy Jennifer A. Woyach, Kelly Smucker, Lisa L. Smith, Arletta Lozanski, Yiming Zhong, Amy S. Ruppert, David Lucas, Katie Williams, Weiqiang Zhao, Laura Rassenti, Emanuela Ghia, Thomas J. Kipps, Rose Mantel, Jeffrey Jones, Joseph Flynn, Kami Maddocks, Susan O’Brien, Richard R. Furman, Danelle F. James, Fong Clow, Gerard Lozanski, Amy J. Johnson, and John C. Byrd
منابع مشابه
Regular Article CLINICAL TRIALS AND OBSERVATIONS Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Bruton tyrosine kinase (BTK) is a critical enzyme in the B-cell receptor signaling pathway and is a novel therapeutic target in CLL. Ibrutinib (previously known as PCI-32765) is an irreversible BTK inhibitor that binds to cysteine 481 within the adenosine triphosphate binding site of the kinase domain. Ibrutinib given at a daily dose of 420 mg received an accelerated approval by the US Food and...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia
Alemtuzumab therapy is effective for some refractory chronic lymphocytic leukemia (CLL), but identifying responders requires at least 8 weeks of therapy. Early identification of nonresponders would minimize toxicity and/or facilitate more effective strategies. The aim of this study was to identify a minimally invasive method for early prediction of response and relapse. Flow cytometric monitori...
متن کاملS100A1 gene therapy for heart failure: a novel strategy on the verge of clinical trials.
Representing the common endpoint of various cardiovascular disorders, heart failure (HF) shows a dramatically growing prevalence. As currently available therapeutic strategies are not capable of terminating the progress of the disease, HF is still associated with a poor clinical prognosis. Among the underlying molecular mechanisms, the loss of cardiomyocyte Ca(2+) cycling integrity plays a key ...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study Samantha M. Jaglowski, Jeffrey A. Jones, Veena Nagar, Joseph M. Flynn, Leslie A. Andritsos, Kami J. Maddocks, Jennifer A. Woyach, Kristie A. Blum, Michael R. Grever, Kelly Smucker, Amy S. Ruppert, Nyla A. Heerema, Gerard Lozanski, Mona Stefanos, Brian Munneke, Jamie-Sue We...
متن کاملPersonalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
In the last 6 years, since the first reports of an association between somatic mutations in epidermal growth factor receptor (EGFR) exons 19 and 21 and response to EGFR tyrosine kinase inhibitors (TKIs), treatment of non-small cell lung cancer (NSCLC) has changed dramatically. Based on laboratory and clinical observations, investigators have anticipated that these mutations could be predictive ...
متن کامل